Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H et al
PMID: 19159808] [Ramachandran L1, Krishnan CV, Nair CK
Rx Only Takeda PRINCIPAL DISPLAY PANEL - Kit Carton - 750 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4626-01 Single-dose only For Intravenous Administration After Reconstitution Only Lyophilized powder for reconstitution ADYNOVATE and diluent preassembled in BAXJECT III system Rx Only Actual potency Takeda PRINCIPAL DISPLAY PANEL - Barrel Label - 750 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Directions for use: see package insert Rx Only IU: LOT: EXP: Takeda 6521228 PRINCIPAL DISPLAY PANEL - Blister Label - 750 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4626-02 Single-dose only 6521490 For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Do not open until time of use Do not use if packaging is opened or damaged Discard unused portion
The mechanisms that may contribute to the induction of oxidative damage in diabetic patients include hyperglycemia-induced glucose auto-oxidation, non-enzymatic glycation of proteins and lipids, increased sorbitol pathway activity, oxidation of AGEs, and formation of prostaglandin H2 (PGH2) [311]
US$ 24.03
US$ 29.58
US$ 29.33
US$ 27.33
US$ 22.58
US$ 20.77
US$ 23.76
US$ 20.05
US$ 20.73
US$ 24.64
